Abstract 4632
Background
Adjuvant dose-dense chemotherapy improves breast cancer (BC) outcomes compared to standard chemotherapy, with no increase in chemotherapy-induced amenorrhea (CIA). However, the impact of menopausal status and the contribution of CIA to outcomes per subtype remain unclear.
Methods
PANTHER is a phase 3 trial comparing tailored, according to hematologic nadirs, and dose-dense (tdd) epirubicin/cyclophosphamide (EC) and docetaxel (D) versus standard interval FEC/D. The primary endpoint of the trial is relapse-free survival (BCRFS). This exploratory secondary analysis aimed to evaluate whether there was differential efficacy of tdd therapy according to menopausal status and if differences in CIA, defined as amenorrhea at 2 years following treatment, may contribute to its efficacy.
Results
Baseline menopause status was available for 1913 women; 1036 premenopausal and 877 postmenopausal. Median follow-up was 5.3 years. The administration of tdd EC/D was associated with a non-statistically significant improvement in BCRFS in both premenopausal (HR = 0.83, 95% CI 0.59 – 1.16, p = 0.265) and postmenopausal patients (HR = 0.74, 95% CI 0.51 – 1.06, p = 0.102; pinteraction0.658). On the contrary, a significant interaction was noticed in women with triple negative BC (TNBC, p = 0.043). Tdd EC/D improved BCRFS in postmenopausal women (HR = 0.44, 95% CI 0.19 – 1.03, p = 0.06) but had a trend to opposite effect among premenopausal women (HR = 1.29, 95% CI 0.69 – 2.40, p = 0.426). There was no difference in CIA rates between the two treatment groups (OR = 1.04, 95% CI 0.77 – 1.39).
Conclusions
Tdd EC/D was associated with non-significant improvements in BCRFS, regardless of menopause status, without increasing rates of CIA. Negative effect on TNBC could be a chance finding due to low number of patients but the results warrant caution and necessitate further investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Swedish Cancer Society, Swedish Breast Cancer Association (BRO), Radiumhemmet Research funds, Amgen, Roche, Sanofi-Aventis.
Disclosure
G. Steger: Honoraria (self): Amgen. R. Greil: Honoraria (self): Amgen; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self): MSD; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Celgene; Honoraria (self): BMS; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: AstraZeneca; Travel / Accommodation / Expenses: Janssen; Research grant / Funding (self): Roche; Research grant / Funding (self): BMS; Research grant / Funding (self): AstraZeneca. S. Loibl: Research grant / Funding (institution): Vigor; Honoraria (institution): AstraZeneca; Honoraria (institution): Amgen; Honoraria (institution): Pfizer; Honoraria (institution): Roche; Honoraria (institution): Puma; Honoraria (institution): Novartis; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Amgen; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Roche; Advisory / Consultancy: Puma; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Celgene; Travel / Accommodation / Expenses: Novartis; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Teva. M. Gnant: Honoraria (self), Travel / Accommodation / Expenses: Amgen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self): Celgene; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Lilly; Honoraria (self): Invectys; Honoraria (self), Travel / Accommodation / Expenses: Pfizer; Honoraria (self): Nano string; Honoraria (self): Novartis; Honoraria (self), Travel / Accommodation / Expenses: Roche; Honoraria (self): Medison; Travel / Accommodation / Expenses: Ipsen; Travel / Accommodation / Expenses: Medison. V. Moebus: Honoraria (self): Amgen; Honoraria (self): Celgene; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Myelotherapeutics; Honoraria (self): AstraZeneca. T. Foukakis: Honoraria (self), Research grant / Funding (institution): Roche; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self): Novartis; Honoraria (self): UptoDate. J. Bergh: Research grant / Funding (institution): Merck; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Sanofi-Aventis; Honoraria (self): Uptodate. All other authors have declared no conflicts of interest.
Resources from the same session
2672 - Changes in clinico-pathological characteristics of vulvar cancer in Japan: increasing oldest-old, stage-shifting, and decreasing cohort-level survival
Presenter: Shin Nishio
Session: Poster Display session 2
Resources:
Abstract
4306 - Tumor Treating Fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: Phase 3 INNOVATE-3/ENGOT-ov50 study
Presenter: Ignace Vergote
Session: Poster Display session 2
Resources:
Abstract
5136 - Randomized, phase 1b/2 study of M6620 + avelumab + carboplatin vs standard care (sc) in patients (pts) with platinum-sensitive poly (ADP-ribose) polymerase inhibitor-(PARPi)-resistant ovarian cancer
Presenter: Susana Banerjee
Session: Poster Display session 2
Resources:
Abstract
2296 - An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: A Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION
Presenter: Jung-Yun Lee
Session: Poster Display session 2
Resources:
Abstract
2732 - A phase 2 study of pembrolizumab in combination with doxorubicin in advanced, recurrent or metastatic endometrial cancer
Presenter: Ana Oaknin
Session: Poster Display session 2
Resources:
Abstract
4404 - ENGOT-EN9/LEAP-001: a phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer
Presenter: Christian Marth
Session: Poster Display session 2
Resources:
Abstract
4564 - Phase 1/2 trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8)
Presenter: Ignace Vergote
Session: Poster Display session 2
Resources:
Abstract
4933 - Updated data of Epitopes-HPV02 trial and external validation of efficacy of DCF in prospective Epitopes-HPV01 study in advanced anal squamous cell carcinoma. Pooled analysis of 115 patients
Presenter: Stefano Kim
Session: Poster Display session 2
Resources:
Abstract
2301 - Pre-specified pilot analysis of a randomised pilot/phase II/III trial comparing standard dose vs dose-escalated concurrent chemoradiotherapy (CRT) in anal cancer (PLATO-ACT5)
Presenter: Alexandra Gilbert
Session: Poster Display session 2
Resources:
Abstract
5773 - A prospective study of diffusion-weighted magnetic resonance imaging for predicting outcome following chemoradiotherapy, in squamous cell carcinomas of the anus.
Presenter: Rebecca Muirhead
Session: Poster Display session 2
Resources:
Abstract